| scholarly article | Q13442814 |
| P50 | author | Tomris Ozben | Q57056671 |
| P2093 | author name string | Aysegul Cort | |
| P2860 | cites work | Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 |
| Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family | Q24320301 | ||
| Nanomedicine therapeutic approaches to overcome cancer drug resistance | Q27011692 | ||
| Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 | ||
| Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain | Q28279190 | ||
| Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin | Q42708720 | ||
| Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro | Q42710220 | ||
| Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin | Q42930932 | ||
| Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. | Q43183047 | ||
| Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1. | Q43628425 | ||
| Cisplatin resistance associated with PARP hyperactivation | Q43703967 | ||
| Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance | Q43705119 | ||
| Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity | Q44071558 | ||
| Role reversal for anticancer agents | Q44216783 | ||
| Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport | Q44327422 | ||
| Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells | Q44812622 | ||
| N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors | Q46165176 | ||
| Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids. | Q46509981 | ||
| Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition | Q46711298 | ||
| New approach to vital analysis of functional activity in ABC transporters (markers for multidrug resistance) in solid tumors by the method of flow cytofluorometry. | Q52011105 | ||
| The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. | Q53988288 | ||
| Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A | Q54307469 | ||
| Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia. | Q54342978 | ||
| Diarylheptanoids from the bark of black alder inhibit the growth of sensitive and multi-drug resistant non-small cell lung carcinoma cells. | Q54513213 | ||
| Effects of Ganoderic acid Me on inhibiting multidrug resistance and inducing apoptosis in multidrug resistant colon cancer cells | Q57699849 | ||
| Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor | Q58053593 | ||
| Reversal of multidrug resitance by natural substances from plants | Q28288384 | ||
| PLGA-carbon nanotube conjugates for intercellular delivery of caspase-3 into osteosarcoma cells | Q28535820 | ||
| Targeting multidrug resistance in cancer | Q29616803 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Structural, mechanistic and clinical aspects of MRP1. | Q33784449 | ||
| The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice | Q33973722 | ||
| Pharmacological strategies for overcoming multidrug resistance | Q33997660 | ||
| Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein | Q33999305 | ||
| Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors | Q34002798 | ||
| Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs | Q34060806 | ||
| Nanoparticle delivery of cancer drugs. | Q34213157 | ||
| Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer | Q34308770 | ||
| Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). | Q34312254 | ||
| The PARP superfamily | Q34335821 | ||
| Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 | Q34360283 | ||
| The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. | Q34388548 | ||
| Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine | Q34419681 | ||
| Role of ABCG2/BCRP in biology and medicine | Q34482976 | ||
| Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters | Q34578109 | ||
| Phase II trial of curcumin in patients with advanced pancreatic cancer | Q34796370 | ||
| Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. | Q34811676 | ||
| Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. | Q35048738 | ||
| The reversal of multidrug resistance: an update | Q35118813 | ||
| Multidrug resistance reversal agents | Q35570886 | ||
| Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer | Q35604870 | ||
| Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). | Q35644367 | ||
| Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy | Q35915497 | ||
| ABC transporters in the balance: is there a role in multidrug resistance? | Q36018461 | ||
| Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. | Q36019240 | ||
| PARP inhibitors for cancer therapy. | Q36100834 | ||
| The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology | Q36336016 | ||
| Current status on marine products with reversal effect on cancer multidrug resistance | Q36395803 | ||
| Mechanisms and strategies to overcome multiple drug resistance in cancer | Q36404538 | ||
| Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis | Q36473635 | ||
| 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. | Q39679819 | ||
| Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. | Q39704866 | ||
| Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells | Q39874352 | ||
| Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids | Q39914317 | ||
| Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds | Q40001475 | ||
| Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells | Q40082780 | ||
| Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells | Q40194598 | ||
| Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. | Q40234208 | ||
| P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. | Q40271526 | ||
| A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). | Q40591949 | ||
| Cancer multidrug resistance | Q40827165 | ||
| Potent interaction of flavopiridol with MRP1 | Q40927437 | ||
| ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. | Q40962980 | ||
| Clinical trials of P-glycoprotein reversal in solid tumours | Q41078214 | ||
| Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport | Q41204990 | ||
| Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism | Q41436320 | ||
| P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain | Q41869168 | ||
| Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport | Q42029507 | ||
| Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells | Q42232521 | ||
| Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport | Q42445797 | ||
| Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. | Q42463356 | ||
| The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology | Q36496323 | ||
| Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models | Q36552134 | ||
| Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. | Q36854285 | ||
| Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges | Q37076348 | ||
| A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair | Q37203855 | ||
| Design of new drug molecules to be used in reversing multidrug resistance in cancer cells | Q37481506 | ||
| Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models | Q37610100 | ||
| Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance | Q37610933 | ||
| Multidrug resistance in cancer | Q37641842 | ||
| Reversing agents for ATP-binding cassette drug transporters | Q37641851 | ||
| Mechanisms of resistance to HER family targeting antibodies | Q37671920 | ||
| Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). | Q37818370 | ||
| Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer | Q37869444 | ||
| Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. | Q37872472 | ||
| The P-glycoprotein multidrug transporter. | Q37941756 | ||
| The potential of exploiting DNA-repair defects for optimizing lung cancer treatment | Q37983690 | ||
| Targeting carbon nanotubes against cancer. | Q37994689 | ||
| Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives | Q38059498 | ||
| Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics | Q38073478 | ||
| Different strategies to overcome multidrug resistance in cancer | Q38117022 | ||
| P-glycoprotein Inhibition for Optimal Drug Delivery. | Q38136183 | ||
| Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down? | Q38137562 | ||
| Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis | Q38157517 | ||
| Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells | Q38334148 | ||
| Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. | Q38343076 | ||
| Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux | Q38990320 | ||
| By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells | Q39062731 | ||
| Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance. | Q39065382 | ||
| Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery | Q39079389 | ||
| miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). | Q39095757 | ||
| HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein | Q39153531 | ||
| Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. | Q39171189 | ||
| Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells | Q39262864 | ||
| Particle carriers for combating multidrug-resistant cancer | Q39317767 | ||
| Reversal effects of components from the fruits of Illicium simonsii on human Adriamycin-resistant MCF-7 and 5-fluorouracil-resistant Bel7402 cells. | Q39466977 | ||
| P433 | issue | 3 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| natural product | Q901227 | ||
| P304 | page(s) | 411-423 | |
| P577 | publication date | 2015-02-03 | |
| P1433 | published in | Nutrition and Cancer | Q7070508 |
| P1476 | title | Natural product modulators to overcome multidrug resistance in cancer | |
| P478 | volume | 67 |
| Q90567303 | Achillin Increases Chemosensitivity to Paclitaxel, Overcoming Resistance and Enhancing Apoptosis in Human Hepatocellular Carcinoma Cell Line Resistant to Paclitaxel (Hep3B/PTX) |
| Q39214227 | Anti-Cancer Phytometabolites Targeting Cancer Stem Cells |
| Q54962852 | Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence. |
| Q37002946 | Cancer Prevention: Obstacles, Challenges and the Road Ahead. |
| Q58724813 | DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride |
| Q36502153 | Efficacy of traditional Chinese medicine in treating cancer |
| Q35983725 | Fallopia japonica, a Natural Modulator, Can Overcome Multidrug Resistance in Cancer Cells |
| Q38697712 | Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells |
| Q33834080 | Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. |
| Q26784161 | Overcome Cancer Cell Drug Resistance Using Natural Products |
| Q26765805 | Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants |
| Q26766724 | South Asian Medicinal Compounds as Modulators of Resistance to Chemotherapy and Radiotherapy |
| Q36680180 | Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance |
Search more.